Diamondback Energy Inc vs Cassava Sciences Inc — how do they compare? Diamondback Energy Inc trades at $191.13 (market cap $53.38B), while Cassava Sciences Inc trades at $1.08 (market cap $53.14M). The key difference: Diamondback Energy Inc is far larger — about 1004.5× Cassava Sciences Inc's market cap, and Diamondback Energy Inc pays a 2.32% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FANG | FLNA | |
|---|---|---|
Market Cap | $53.38B | $53.14M |
Sector | Energy | Health |
52-Week High | $213.69 | $4.64 |
52-Week Low | $134.53 | $1.09 |
Enterprise Value | $67.11B | -$33.43M |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $191.28, up 0.31% on the day, with a bullish technical signal and strong analyst support. Recent earnings show mixed results, beating estimates in Q1 2026 but missing in Q4 2025, while revenue growth remains robust. The company maintains solid cash flow from operations and a manageable debt-to-asset ratio of 22.26% as of 2025. A dividend of $1.10 was recently declared, with the next earnings report scheduled for August 3, 2026.
FANG presents a favorable outlook with a consensus price target of $234.50, implying 22.6% upside, supported by 90% buy ratings from analysts. Risks include volatile oil prices, geopolitical factors affecting energy markets, and declining net income margins. The stock's high P/E ratio of 193.63 warrants caution, but strong operational cash flow and institutional bullishness provide a solid foundation for growth-oriented investors.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Trailing returns across standard periods
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →